Moreover, ovarian cancer patients with high MYC mRNA levels tend to have lower disease-free (DFS) and the overall survival (OS) compared with their counterparts; thus, MYC may serve as a potential therapeutic target for ovarian cancers expressing high levels of this oncoprotein [50]. The gene discussed is MYC; the disease is ovarian carcinoma.